Genomics and Population Health Action Collaborative
Cascade Screening (March 2017-Present)
|Heather Hampel, M.S., L.G.C.
Licensed Genetic Counselor, Clinical Cancer Genetics Program
Professor, Division of Human Genetics
Department of Internal Medicine
The Ohio State University
Co-Leader, Cascade Screening Working Group
Founder and CEO
The FH Foundation
Co-Leader, Population Screening Working Group
The Cascade Screening Working Group is focused on developing tools and best practices for the identification and genetic testing of at-risk relatives of those individuals diagnosed with familial hypercholesterolemia (FH), Lynch syndrome (LS), and/or hereditary breast and ovarian cancer (HBOC). The idea behind cascade screening is that it can provide early diagnosis and disease management and ultimately reduce morbidity and mortality from high-risk genetic conditions. The Working Group will explore the state of the science on cascade screening and examine specific examples of cascade testing that have taken place outside of the US. This information will be utilized in the design of a roadmap for pilot cascade screening programs that will focus on cardiovascular disease (in the case of FH) or cancer (for LS and HBOC).
For more information about the Genomics and Population Health Action Collaborative, please click here.